A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 502 participants.

Also called NCT05646381

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 502 participants (planned count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT05646381
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Austria, Belgium, Canada, Czechia, Denmark, France, Germany, Israel, Italy, Netherlands, Portugal, Spain, Switzerland, United Kingdom (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05646381. Randomized; double masking; primary purpose treatment. Start 2024-03-07 (actual); primary completion 2030-03-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis
Condition
Aortic Stenosis
Intervention (Drug)
Pelacarsen (TQJ230) 80mg
Intervention (Drug)
Matching placebo
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct05646381
Content hash
f86e14f725abf84e290286f09eeed55894c0ab2219309fbdede67863691ea199